1. Home
  2. CRBP vs BAFN Comparison

CRBP vs BAFN Comparison

Compare CRBP & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$5.42

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$5.40

Market Cap

175.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
BAFN
Founded
2009
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
175.3M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
CRBP
BAFN
Price
$5.42
$5.40
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
★ $34.03
N/A
AVG Volume (30 Days)
★ 1.1M
127.7K
Earning Date
11-11-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 97.62
N/A
52 Week Low
$5.13
$4.26
52 Week High
$20.56
$10.38

Technical Indicators

Market Signals
Indicator
CRBP
BAFN
Relative Strength Index (RSI) 23.84 32.64
Support Level N/A $4.53
Resistance Level $8.13 $6.75
Average True Range (ATR) 0.42 0.78
MACD -0.10 -0.24
Stochastic Oscillator 10.17 0.00

Price Performance

Historical Comparison
CRBP
BAFN

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.

Share on Social Networks: